Seeking Alpha

Morgan Stanley resumes coverage of Pfizer (PFE +0.1% to $28.37) at Overweight and gives the...

Morgan Stanley resumes coverage of Pfizer (PFE +0.1% to $28.37) at Overweight and gives the company a price target of $31.00. The rating comes as the EU authorizes the expanded use of Pfizer's blockbuster anti-bacterial vaccine Prevenar 13. Thirteen analysts rate Pfizer a Buy, six a Hold and two a Sell.
Comments (1)
  • Ed Rudy, WWW.EdRudy.com
    , contributor
    Comments (445) | Send Message
     
    Morgan Stanley coverage, precipitated by approval of Pfizer's new blockbuster drug PROVENAR, will add to the upward impetus of Pfizer's price and dividends.
    Buy Pfizer (PFE).
    10 Jul 2013, 09:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|